PROGNOSTIC SIGNIFICANSE OF THE POLYMORPHISM OF GENES ASSOCIATED WITH THE RISK OF TYPE 2 DIABETES MELLITUS AND OBESITY, FOR THE DEVELOPMENT OF LIVER FIBROSIS AND HEPATIC STEATHOSIS IN PATIENTS WITH NON-ALCOHOLIC FAT LIVER DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The present study was conducted to assess the effect of polymorphism of the PPARGC1A, PPARGC1B, PPARG2 and FTO genes in patients with type 2 diabetes mellitus (DM2) on the development of liver fibrosis and hepatic steatosis. 62 DM2 patients aged from 29 to 82 years underwent complex examination. A screening assessment of hepatic steatosis and liver fibrosis in DM2 patients was performed with the use of non-invasive methods: a panel of laboratory tests (FibroTest), and liver fibroelastometry. Polymorphism of genes determining hereditary predisposition to obesity and DM2: PPARGC1A (peroxisome activator 1a receptor co-activator - Gly482Ser polymorphism (G>A), PPARGC1B (peroxisome proliferator-activated 1a receptor co-activator, Al203Pro polymorphism, G>C), PPARG2 (PPAR-gamma transcription factor, Pro12Ala polymorphism), FTO (obesity-associatedgene, c.IVS1 polymorphism A>T) was evaluated. The statistical analysis was carried out using the Mann-Whitney-Wilcoxon test, Pearson’s criterion and logistic regression. As a result of examination, patients with variants of PPARGC1A, PPARGC1B, PPARG2 and FTO genes that determine an increased risk of developing DM2 and obesity were noted to have no increased risk of progression of liver fibrosis.

Full Text

Restricted Access

About the authors

Yu. G Sandler

SBHCI “Moscow Clinical Research Center n.a. A.S. Loginov" of Moscow Healthcare Department

Email: sandlerjulia2012@gmail.com

A. V Polukhina

SBHCI “Moscow Clinical Research Center n.a. A.S. Loginov" of Moscow Healthcare Department

E. V Vinnitskaya

SBHCI “Moscow Clinical Research Center n.a. A.S. Loginov" of Moscow Healthcare Department

I. G Bakulin

North-Western State Medical University n.a. I.I. Mechnikov

Zh. V Borunova

SBHCI “Moscow Clinical Research Center n.a. A.S. Loginov" of Moscow Healthcare Department

V. A Keyyan

SBHCI “Moscow Clinical Research Center n.a. A.S. Loginov" of Moscow Healthcare Department

References

  1. Briohny W. Smith & Leon A. Adams. Non-alcoholic fatty liver disease. Critical Rev. Clin. Laborat. Sci. 201;8:97-113
  2. Романцова Т.И. Эпидемия ожирения: очевидные и вероятные причины. Ожирение и метаболизм. 2011;1:5-19.
  3. Бакулин И. Г., Сандлер Ю. Г., Винницкая Е. В., Кейян В. А., Драпун С. В. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? Доктор.Ру. Гастроэнтерология. 2015;12:57-64.
  4. Бакулин И.Г., Сандлер Ю.Г., Кейян В.А., Ротин Д.Л. Новый неинвазивный метод оценки стеатоза при хронических заболеваниях печени. Тер. архив. 2016;88(2):49-57
  5. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). РЖГГК. 2014;24(4):32-8.
  6. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Диагностика неалкогольной жировой болезни печени с использованием методов неинвазивного скрининга населения. Врач. 2010;(12):13-9.
  7. Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Бращенкова А.В. Неалкогольная жировая болезнь печени: клиника, диагностика и лечение. Леч. врач. 2008;2.
  8. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J. D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology. 2004;(40):1387-95.
  9. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., Hobbs H.H., Dobbins R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005;(288):462-68.
  10. Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 2013;(58): 593-608.
  11. Fassio E., Alvarez E., Dominguez N., Landeira G., Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;(40):820-26.
  12. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
  13. Visscher P.M., Hill W.G., Wray N.R. Heritability in the genomics era-concepts and misconceptions. Nat. Rev. Genet. 2008;9:255-66.
  14. Ожирение и избыточный вес. Информационный бюллетень ВОЗ №311, май 2014.
  15. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
  16. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008;40:1461-65.
  17. Palmer C.N.A., Maglio C., Pirazzi C., Burza M.A., Adiels M., Burch L., et al. Paradoxical Lower Serum Triglyceride Levels and Higher Type 2 Diabetes Mellitus Susceptibility in Obese Individuals with the PNPLA3 148M Variant. PLoS ONE. 2012;7(6):e39362.
  18. Donati B., Motta B.M., Pingitore P., Meroni M., Pietrelli A., Alisi A., et al. The rs2294918 E434K variant modulates PNPLA3 expression and liver damage. Hepatology. 2016;63:787-98.
  19. Scorletti E., West A.L., Bhatia L., Hoile S.P., McCormick K.G., Burdge G.C., Lillycrop K.A., Clough G.F., Calder P.C., Byrne C.D. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J. Hepatology. 2015;63(6):1476-83.
  20. Sookoian S., Castaho G.O., Scian R., Mallardi P., Fernandez Gianotti T., Burgueho A.L., San Martino J., Pirola C.J. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61:515-25.
  21. Ridderstrâle M., Johansson L.E., Rastam L., Lindblad U. Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men. Diabetologia. 2006;49:496-500.
  22. Yoneda M., Hotta K., Nozaki Y., Endo H., Uchiyama T., Mawatari H., Iida H., Kato S., Hosono K., Fujita K., Yoneda K., Takahashi H., Kirikoshi H., Kobayashi N., Inamori M., Abe Y. Kubota K., Saito S., Maeyama S., Wada K., Nakajima A. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology. 2008;1:27.
  23. Ek J., Andersen G., Urhammer S.A., Gaede P.H., Drivsholm T., Borch-Johnsen K., Hansen T., Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001; 44:2220-26.
  24. Younossi Z.M., Diehl A.M., Ong J.P Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-52.
  25. Leone T.C., Lehman J.J., Finck B.N., Schaeffer P.J., Wende A.R., Boudina S., Courtois M., Wozniak D.F., Sambandam N., Bernal-Mizrachi C., Chen Z., Holloszy J.O., Medeiros D.M., Schmidt R.E., Saffitz J.E., Abel E.D., Semenkovich C.F., Kelly D.P PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005;3:e101-10.1371.
  26. Andersen G., Wegner L., Yanagisawa K., Rose C., Lin J., Glumer C., Drivsholm T., Borch-Johnsen K., Jorgensen T., Hansen T., Spiegelman B., Pedersen O. Evidence of an association between genetic variation of the coactivator PGC-1 ß and obesity. J. Med. Genet. 2005;42(5):402-7.
  27. Dongiovanni P., Rametta R., Fracanzani A.L., Benedan L., Borroni V., Maggioni P., Maggioni M., Fargion S., Valenti L. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology. 2010;10:102.
  28. Frayling T.M., Timpson N.J., Weedon M.N., et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826): 889-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies